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Uterine perivascular epithelioid cell tumors (PEComas) are rare neoplasms.
PI3K/AKT/mTOR pathway upregulation is critical for their pathogenesis and is
often associated with TSC1/TSC2 inactivation. Although first line mTOR inhibitors
are an effective treatment, metastatic PEComas eventually progress. A 53-year-old
woman presented a 4-month history of post-menopausal vaginal bleeding. Clinical and
radiological examination detected a uterine mass and a single S1 bone lesion. The
patient underwent a radical hysterectomy and bone biopsy. The anatomopathological
evaluation concluded to an oligo-metastatic uterine PEComa. The tumor harbored a
heterozygous deletion of 9q34 that contains the TSC1 gene. Concerning the primary
lesion, the resection was complete and the single bone metastasis was treated with
radiotherapy. Three months later, the patient presented bone, lung and subcutaneous
metastatic progression. An everolimus and denosumab treatment was initiated. After
2 years of treatment, a clinically significant bone, lung and subcutaneous progression
was detected. Following a literature review of the possible therapeutic options, we
initiated a second line treatment by pazopanib. This treatment resulted in regression of
the subcutaneous lesions and stability of lung and bone metastases. In this challenging,
rare setting, our report suggests single agent, anti-angiogenic, tyrosine kinase inhibitor
to be effective as second line treatment of metastatic uterine PEComa progressing on
mTOR inhibitors.
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INTRODUCTION
Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors, originating from
the perivascular epithelioid cell-line (PEC) (1, 2). PEComas are characterized by co-expression
of melanocytic and myoid markers including actin, desmin, HMB-45, and Melan-A (3). S100
and CK are rarely expressed (4). The World Health Organization (WHO) defines PEComas
as “mesenchymal tumors composed of histologically and immunohistochemically distinctive
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FIGURE 1 | Initial pathology.
perivascular cells.” PEComas is a relatively new subgroup of
tumors, first described in 1992. Under the initial description,
PEComas only included angiomyolipoma (AML) and
clear cell “sugar” tumor of the lung (CCST). Currently,
lymphangioleiomyomatosis (LAM) has also been added to the
PEComa family (4, 5). Although not all subsets of PEComas
present malignant behavior, a considerable proportion exhibit
malignant features including high proliferation rate and
cytological atypia.
PEComas can occur at any age, but they are more common in
the fourth decade. They affect more often women, which suggests
a potential role of hormones in pathogenesis (6, 7). PEComas
have tropism for the retroperitoneum, the kidneys and the
genitourinary tract, but rarely can affect other localizations. As far
as uterine PEComas are concerned, they are usually located in the
corpus. Rarely the uterine cervix can also be involved (1, 5). The
differential diagnosis of uterine PEComas is large and includes
all types of uterine malignant and benign tumors. Especially
challenging is their radiological distinction from smooth muscle
tumors namely leiomyomas, a frequent benign tumor present
in up to 80% of middle age women (8). PEComas can also be
misdiagnosed for carcinomas, especially if visceral or cervical
involvement is present, mimicking clear cell or other subtypes
radiological characteristics.
The pathogenesis of PEComas is not yet fully understood.
It has been hypothesized that these tumors are associated with
tuberous sclerosis complex (TSC). This tumor-suppressor gene
syndrome is caused by inactivation of TSC1 and TSC2, encoding
hamartin and tuberin, respectively (9). These two proteins
form a heterodimeric complex with inhibitor effect to the
mammalian target of rapamycin (mTOR) activity. Inactivation
of the tuberin/hamartin complex, results from a germline
and /or loss-of-function mutation of either TSC1 or TSC2
genes. Subsequent permanent activation of mTOR promotes cell
growth. Similar mutations have also been detected in sporadic,
not associated with TSC, PEComas (10, 11).
Many different angiogenesis inhibitors were reported effective
for advanced PEComa treatment (4). Angiogenesis is a complex
web of cytokines and receptors with intracellular and nuclear
cascades for signal transmission. They are intimately related to
tumor genesis, proliferation and invasion. Vascular endothelial
growth factor (VEGF) over-expression is a prognostic factor,
associated with increased risk of metastases and decreased overall
survival, in patients with solid tumors. The VEGF receptors
(VEGFR) are a family of tyrosine kinase (TK) receptors that
include VEGFR-1, VEGFR-2, and VEGFR-3 expressed among
tumor microenvironment stromal cells and endothelial cells. The
platelet derived growth factor (PDGF) and its receptor (PDGFR)
family includes PDGFR, c-Kit, and Flt-3. Their main effect is the
proliferation and migration of cells.
The treatment of PEComas can be challenging, as there
are no prospective trials nor established standard treatment
guidance. Despite mTOR inhibitors, resistant or progressive
diseases treatment is unclear. In this challenging context,
where commonly used chemotherapies including anthracyclines,
taxanes, and anti-metabolites have marginal or no effect,
prospective research is urgently needed to determine second
line treatment options (12). In our report, we present the
efficacy of the 2nd line treatment by pazopanib, a multi-tyrosine
kinase inhibitor, in a patient with a metastatic uterine PEComa,
progressing after 2 years of everolimus treatment.
CASE REPORT
A 53 year-old woman presented a 4-month history of vaginal
bleeding without associated abdominal pain or other symptoms.
On the gynecological examination, a right side, para-uterinemass
was detected. The vaginal ultrasound and MRI showed the 6
× 6 cm mass with no associated lymph node involvement. The
PET-CT identified a single bone lesion in the sacral spine (S1).
Tumor markers including CEA, CA125, CA19-9, and CA15-3
were within normal range.
The patient underwent radical hysterectomy and bone biopsy.
Both bone biopsy and hysterectomy indicated an oligo-metastatic
uterine PEComa, without cervical involvement, with high-grade
nuclear features and lymphovascular invasions (Figure 1). The
tumor expressed CD10, the myoid smooth muscle actin and
HMB45. Focal anti-TFE3 was also observed (11, 13). The single
bonemetastasis was treated with radiotherapy (5 fractions of 7Gy
for a total of 35 Gy).
Three months later, the patient presented asymptomatic
bone, lung and subcutaneous recurrence. Targeted NGS (52-
cancer gene hotspot panel) detected no mutation but a
heterozygous deletion of 9q34 that contains the TSC1 gene
(Figure 2) (14), prompting a first line everolimus treatment
(10mg 1×/day, po) (15). For the bone metastasis, denosumab
(120mg 1/month sc) was initiated, and a quarterly follow-
up by PET-CT as well as regular clinical surveillance was
decided. On this treatment, the disease was controlled for
2 years, but unfortunately the patient started feeling pain
in the subcutaneous lesion of the right thigh and clinical
progression was noted. The PET-CT showed bone, lung and
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FIGURE 2 | NGS 400 genes.
subcutaneous progression. A second line treatment by pazopanib
and denosumab was introduced, based on reports on anti-
angiogenic tyrosine kinase inhibitors (TKIs) effect in PEComas
(16, 17) (Table 1).
During the treatment, the patient had regular clinical,
biological and radiological controls. With the combination of
pazopanib (800mg 1×/day po) and denosumab, there was
regression of the subcutaneous disease and stability of lung and
bone metastasis for over a year Figure 3. It is important to
note that all the treatments were well-tolerated, only with mild
toxicities. No dose adaptation was necessary.
DISCUSSION
Both sporadic and TSC associated PEComas present mTOR
pathway alterations. This provided the rational for rather
successful use of mTOR inhibitors including sirolimus,
everolimus or temsirolimus. Despite being a rare tumor
with no specific randomized controlled trial assessing
the optimal treatment sequence, mTOR inhibitors are
currently considered the most effective treatment option
for metastatic PEComas (25–29). In the case of our patient,
single agent everolimus treatment at the standard dose
of 10mg per day was effective for up to 2 years Albeit
this observation, it should be noted that in the reported
cases the response rate and PFS varies, with a PFS of 9
months (4), according to the clinical context and previous
prescribed treatments.
At the time of symptomatic progression, the therapeutic
plan of our patient became even more challenging. Since
no targetable alteration was detected in the 52-genes tumor
DNA sequencing, we underwent a literature review on Scopus
and PubMed. The key word used were “metastatic” and
“PEComa,” “uterine perivascular epithelioid cell tumor,” “soft
tissue sarcomas,” “mTOR,” “treatment.” We selected publications
from 2000 to 2019.
The review pointed out potential benefit from
anti-angiogenic treatment as an effective therapeutic
option for our patient (16, 17). Furthermore, the local
funding system enables pazopanib treatment for soft
tissue sarcomas.
Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor,
which has activity against VEGF-1–3, PDGFRα- β and KIT,
resulting in tumor growth blockage and angiogenesis inhibition.
The Phase III, placebo-controlled, double-blind PALETTE trial,
comparing the efficacy of pazopanib vs. placebo in patients
with non-adipocytic soft tissue sarcoma already treated with
doxorubicin, showed a significant increase in PFS with pazopanib
(4.6 vs. 1.6 months; P < 0.001); ORR was 6%. Median OS
was 12.5 months with pazopanib vs. 10.7 months with placebo,
but was not statistically significant (HR: 0.86, 95% CI: 0.67–
1.11; p = 0.25). There is no precision on whether patients
with PEComas were included in the trial (16). The SPIRE trial
showed the activity of pazopanib in patients with soft tissue
sarcomas, based on reports on specific histological subtypes
(17). Two of the patients included in the trial were diagnosed
with PEComas.
Sunitinib and regorafenib are approved for gastrointestinal
stromal tumor (GIST), but not for other STS, as the clinical trials
of these agents as STS treatment are limited to single-arm phase
II trials (30, 31).
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TABLE 1 | Summary of studies evaluating anti-VEGFR treatments for PEComas/soft tissue sarcomas (18–24).
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FIGURE 3 | Response on pazopanib treatment.
Sorafenib is another multi-TKI that has only showed limited
activity in a phase II trial (32) including patients with six different
types of STS. There was no precision on whether patients with
PEComas were included.
In our review three interesting therapeutic combinations
were included. One case-report reported the combination
of sorafenib with sirolimus as effective palliative therapy in
malignant PEComa (33). In another report bevacizumab, a
monoclonal antibody (MoAb) targeting VEGF was evaluated.
The combination of bevacizumab with doxorubicin was
evaluated in a phase II trial, among 17 patients with metastatic,
anthracycline-naïve, soft tissue sarcomas (34). The overall
response rate was 12%, equal to the observed for single-agent
doxorubicin arm. However, stable disease, lasting four cycles
or longer, was observed in 65% of patients. Interestingly, in a
retrospective case series published in 2018, seven patients with
advanced PEComa progressing on mTOR inhibitor (sirolimus)
were treated with exemestane, an aromatase inhibitor, in
combination with everolimus. Authors reported restoration of
tumors to mTOR inhibitor leading to a median PFS of 7 months
and median duration of the response 11 months (35).
Although with limited impact and no comparison arm, our
treatment decision lead to a 12 months stabilization of our
patient lung and bone disease and notably with regression of her
symptomatic subcutaneous metastasis.
CONCLUSION
PEComas are rare mesenchymal neoplasms, for which there
is no systemic treatment established. Our report provides data
that mTOR inhibitors and anti-angiogenic TKI can be effective
treatments, with an acceptable toxicity profile. Further research
is needed in order establish the optimal treatment sequence in
this setting.
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